<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialRecordsOutput><serviceExecutionTime>235</serviceExecutionTime><Trial id="102343"><TitleDisplay>Dexmedetomidine Versus Propofol for Cerebral Angiography in Pediatric Patients</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">ChiCTR-TRC-12002713</Identifier></Identifiers><Indications><Indication id="19">Anesthesia</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>dexmedetomidine</Name><Drug id="8783">dexmedetomidine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>propofol, AstraZeneca/Fresenius</Name><Drug id="44308">propofol, AstraZeneca/Fresenius</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44308">propofol, AstraZeneca/Fresenius</Drug><IndicationsPioneer/><Companies><Company><Company id="1031298">Soochow University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8783">dexmedetomidine</Drug><IndicationsPioneer/><Companies><Company><Company id="1031298">Soochow University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="8783" type="Drug"><TargetEntity id="145584" type="siDrug">Dexmedetomidine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="44308" type="Drug"><TargetEntity id="90057" type="siDrug">Propofol</TargetEntity></SourceEntity><SourceEntity id="1031298" type="Company"><TargetEntity id="5001203074" type="organizationId">Soochow University</TargetEntity></SourceEntity><SourceEntity id="19" type="ciIndication"><TargetEntity id="10002091" type="MEDDRA"/><TargetEntity id="D000758" type="MeSH"/><TargetEntity id="-564538434" type="omicsDisease"/><TargetEntity id="23" type="siCondition"/></SourceEntity><SourceEntity id="33" type="Action"><TargetEntity id="54" type="Mechanism">alpha2-Adrenoceptor Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1031298">Soochow University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="33">Alpha 2 adrenoceptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1668">General anesthetic</Class><Class id="2942">Anxiolytic</Class><Class id="2944">Hypnotic</Class><Class id="2946">Analgesic</Class><Class id="59620">Unspecified drug target</Class></Class><Technologies><Technology id="740">Infusion</Technology><Technology id="597">Injectable emulsion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="630">Stereochemistry</Technology></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>62</PatientCountEnrollment><DateStart>2011-03-20T00:00:00Z</DateStart><DateEnd type="estimated">2012-05-08T00:00:00Z</DateEnd><DateChangeLast>2017-03-24T09:08:42Z</DateChangeLast><DateAdded>2012-12-26T04:20:28Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Department of Anesthesiology, First Hospital of Soochow University</Affiliation><Email>pengke0422@163.com</Email><Name>Ke Peng</Name><Phone>+86 15962155989</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Aged 3 to 15 years old&lt;/li&gt;&lt;li&gt;ASA physical status I to clas  II&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Known allergic alpha-2 agonists&lt;/li&gt;&lt;li&gt;ASA &gt; class III cardiovascular malformations&lt;/li&gt;&lt;li&gt;Craniofacial abnormalities&lt;/li&gt;&lt;li&gt;Respiratory diseases (pneumonia, asthma, bronchitis, the serious group Cyproit sleep apnea)&lt;/li&gt;&lt;li&gt;Glasgow score&amp;lt; 15&lt;/li&gt;&lt;li&gt;Intracranial hypertension&lt;/li&gt;&lt;li&gt;Uncontrolled epilepsy&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Hemodynamic changes</Description></Measure><Measure><Description>Adverse events</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this randomized, parallel-group, controlled study was to compare the safety and efficacy of &lt;ulink linkType="Drug" linkID="8783"&gt;dexmedetomidine&lt;/ulink&gt; with  &lt;ulink linkType="Drug" linkID="44308"&gt;Diprivan&lt;/ulink&gt; as the sole sedative agent for cerebral angiography in pediatric patients [&lt;ulink linkType="Reference" linkID="1352155"&gt;1352155&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive either &lt;ulink linkType="Drug" linkID="8783"&gt;dexmedetomidine&lt;/ulink&gt; or propofol [&lt;ulink linkType="Reference" linkID="1352155"&gt;1352155&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>The First Affiliated Hospital of Soochow University</Name><Address1>Suzhou</Address1><Address2>Jiangsu</Address2><CountrySubDivision>Jiangsu</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier type="Secondary Organisational">ChiCTR-TRC-12002713</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-12-26T04:20:28Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="154479"><TitleDisplay>Childhood Obesity Management Shifting From Healthcare System to School System: School-Based Weight Management Programme</TitleDisplay><TitleOfficial>Childhood obesity management shifting from healthcare system to school system: school-based weight management programme</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="ISRCTN">ISRCTN58795797</Identifier><Identifier type="Secondary Organisational">CUHK SS06838</Identifier><Identifier type="Secondary Organisational">Project No: 20060524</Identifier></Identifiers><Indications><Indication id="238">Obesity</Indication></Indications><BiomarkerNames><BiomarkerName id="113" role="Therapeutic effect marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="7586" role="Therapeutic effect marker" type="Anthropomorphic">Body fat percentage</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="17697" role="Therapeutic effect marker" type="Anthropomorphic">Body height</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>School-based weight management programme</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1081719" type="Company"><TargetEntity id="5039582638" type="organizationId">Food and Health Bureau Government of Hong Kong Special Administrative Region</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"/><TargetEntity id="10029883" type="MEDDRA"/><TargetEntity id="D009765" type="MeSH"/><TargetEntity id="-1640888899" type="omicsDisease"/><TargetEntity id="985" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1081719">Food and Health Bureau, Hong Kong</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Children (6-12 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Prevention</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>106</PatientCountEnrollment><DateStart>2007-06-01T00:00:00Z</DateStart><DateEnd type="actual">2008-11-30T00:00:00Z</DateEnd><DateChangeLast>2018-07-05T07:07:24Z</DateChangeLast><DateAdded>2013-09-17T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Centre for Health Education and Health Promotion, The Chinese University of Hong Kong, 4/Floor, Lek Yuen Health Centree, Shatin, NA, Hong Kong</Affiliation><Email>alee@cuhk.edu.hk</Email><Name>Albert Lee</Name><Phone>852 26933670</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Overweight and obese students aged between 8 and 12 were recruited from six schools&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Those eligible students who refused to participate&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Standing height (to the nearest cm) was measured with a portable stadiometer (Model: 214, SECA)</Description><Timeframe>Outcome measures were assessed at baseline (T0) before the intervention, and completion of 4-month intervention (T1) to assess the immediate program effectiveness and after a 4-month maintenance period (8 months from baseline, T2) to evaluate the sustainability of the programme</Timeframe></Measure><Measure><Description>Age- and sex-adjusted BMI (BMI z-score) and body fat percentage: body weight (to nearest 0.1 kg) and body fat percentage (to nearest 0.5%) were measured by bio-impedance body fat scale (Model : TBF-521, Tanita, Japan) with participants lightly clothed and without shoes</Description><Timeframe>Outcome measures were assessed at baseline (T0) before the intervention, and completion of 4-month intervention (T1) to assess the immediate program effectiveness and after a 4-month maintenance period (8 months from baseline, T2) to evaluate the sustainability of the programme</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Self reported attitude and behavioral variables: students completed a set of questionnaire adopted from previous studies specially designed for school children containing a total of 20 items to investigate the attitude towards healthy eating and exercise, dietary behaviour, physical activity participation, self-control, self-perception and weight management practice. Parents completed a self-administered questionnaire on the general health condition, eating and exercise habit of their children, cooking methods used at home, frequencies of engaging in different activities (such as housework, outings and sports activities) with their children</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study was to  evaluate the effectiveness of a multi-component school-based weight management programme that aimed to help subjects (primary school children)  with overweight and obesity to achieve the goal of weight control via a home-school joint venture supported by healthcare professionals school-based weight management programme [&lt;ulink linkType="Reference" linkID="1477930"&gt;1477930&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Subjects would receive a school based weight management programme [&lt;ulink linkType="Reference" linkID="1477930"&gt;1477930&lt;/ulink&gt;]. &lt;br/&gt;A total of 57 subjects   would be  randomly selected to participate in the school based programme first with 49 subjects as wait list control who started the programme. Subjects would attend ten 75-min after-school sessions and one 3-h weekend session of practical, interactive and fun activities on healthy eating and exercise. Subjects would  be provided a meal plan at the beginning of the programme together with parents and received printed tailor-made management advices. Parents would receive an introductory seminar with two sets of specially designed exercise for overweight subjects  and further two 1-h follow up sessions on skills about healthy eating and exercise strategies to assist weight control for their children.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Hong Kong"><Sites><Site><Contacts/></Site><Site><Name>Centre for Health Education and Health Promotion, The Chinese University of Hong Kong</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Obesity</Disease><PatientSegments><PatientSegment><PatientSegment id="7733">Overweight (pre-obese) Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7734">Obese Class I Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7735">Obese Class II Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7739">Pediatric Overweight Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7740">Pediatric Obese Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN58795797</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Obesity" id="20392"><Endpoint>Assessment of fat</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Obesity" id="20791"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20400">Assessment of Body Weight</SubEndpoint><SubEndpoint disease="Obesity" id="20405">Assessment of BMI</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Obesity" id="20623"><Endpoint>Assessment of Behavior Changes</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="29701"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="29763">Other patient reported outcomes</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Obesity" id="19672"><Criterion>Obese Subjects</Criterion><SubCriteria><SubCriterion disease="Obesity" id="22429">Obese Class I Subjects</SubCriterion><SubCriterion disease="Obesity" id="22430">Obese Class II Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19787"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Obesity" id="22428">Overweight Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="22431"><Criterion>Pediatric Overweight Subjects</Criterion></Inclusion><Inclusion disease="Obesity" id="22432"><Criterion>Pediatric Obese Subjects</Criterion></Inclusion></InclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2008-11-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>18.00 Months</EnrollmentPeriod><EnrollmentRate>5.89 Patients/Month</EnrollmentRate><FundersType><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-09-17T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="274641"><TitleDisplay>Biomarker study for nivolumab</TitleDisplay><TitleOfficial>The prospective study of plasma biomarker in the patients treated with nivolumab for advanced non-small cell lung cancer</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000021734</Identifier></Identifiers><Indications><Indication id="3665">Metastatic non small cell lung cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="824" role="Therapeutic effect marker" type="Genomic;Proteomic">Programmed cell death 1 ligand 1</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>nivolumab</Name><Drug id="54804">nivolumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="54804">nivolumab</Drug><IndicationsPioneer/><Companies><Company><Company id="1006418">Tokyo Metropolitan Komagome Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="54804" type="Drug"><TargetEntity id="421460" type="siDrug">Nivolumab</TargetEntity></SourceEntity><SourceEntity id="1006418" type="Company"><TargetEntity id="5035531616" type="organizationId">Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital</TargetEntity></SourceEntity><SourceEntity id="3665" type="ciIndication"><TargetEntity id="10059515" type="MEDDRA"/><TargetEntity id="613" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1006418">Tokyo Metropolitan Komagome Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="67136">Programmed cell death protein 1 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="393">Immunostimulant</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="7761">T-lymphocyte stimulator</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="649">Intraperitoneal formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="168">Monoclonal antibody human</Technology><Technology id="746">Solution</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>64</PatientCountEnrollment><DateStart>2016-05-01T00:00:00Z</DateStart><DateChangeLast>2017-08-16T14:10:09Z</DateChangeLast><DateAdded>2016-10-10T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital ; Department of Thoracic Oncology and Respiratory Medicine</Affiliation><Email>y-okuma@cick.jp</Email><Name>Okuma, Yusuke</Name><Phone>03-3823-2101</Phone></Contact><Contact type="Scientific contact"><Affiliation>Research Center for Medical Science, The Jikei University of Medicine ; Division of Oncology</Affiliation><Email>shonma@jike.ac.jp</Email><Name>Honma, Sadamu</Name><Phone>03-3433-1111</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who treated with chemotherapy at Komagome Hospital. Before being underwent chemotherapy, the patients examined blood sample with tube (or EDTA) contains sodium heparin of the 4ml. Then, collected blood samples (upto 32 samples) are exploratory checked for soluble PD-L1 whether it could be detectable or not at Tokyo Jikei University&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Other than that above&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>To investigate correlation between soluble PD-L1 or other biomarkers and clinical response or toxicities</Description></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the present study is to elucidate plasma soluble PD-L1 or other biomaker in the advanced NSCLC (non-small cell lung cancer) patients treated with &lt;ulink linkType="Drug" linkID="54804"&gt;nivolumab&lt;/ulink&gt;.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients with metastatic non small cell lung cancer receiving nivolumab will be enrolled and observed in this study.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Cancer · Infectious Disease Center Tokyo Metropolitan Komagome Hospital</Name><Address1>Tokyo</Address1><Contacts/></Site><Site><Name>Tokyo Jikei University Medical University Medical Science Research Center</Name><Address1>Tokyo</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Lung tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3617">Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3623">Subjects with Advanced Stage Lung Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000021734</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lung tumor" id="8529"><Endpoint>Assessment of Clinical Response</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Lung tumor" id="8629"><Endpoint>Assessment of Biomarkers</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Lung tumor" id="8639"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lung tumor" id="3900"><Criterion>Subjects with Non Small Cell Lung Cancer (NSCLC)</Criterion></Inclusion><Inclusion disease="Lung tumor" id="3940"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Lung tumor" id="3988"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3989">Subjects with history of anti-cancer chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="4073"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="4104">Subjects with tumor tissue/blood sample available for analysis/further assessment</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Lung tumor" id="5344"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-10-10T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-05-02T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="276961"><TitleDisplay>A cohort study of anthracycline-induced cardiotoxicity</TitleDisplay><TitleOfficial>A cohort study of anthracycline-induced cardiotoxicity</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000022984</Identifier></Identifiers><Indications><Indication id="1090">Cardiotoxicity drug-induced</Indication></Indications><BiomarkerNames><BiomarkerName id="1945" role="Disease marker" type="Physiological">Left ventricular ejection fraction</BiomarkerName><BiomarkerName id="10306" role="Disease marker" type="Physiological">Ejection fraction</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>echocardiac examination</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="14929" type="Company"><TargetEntity id="4298193774" type="organizationId">University of Tsukuba</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="14929">University of Tsukuba</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>No Control</Term><Term>Open Label</Term><Term>Diagnosis</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>500</PatientCountEnrollment><DateStart>2016-08-01T00:00:00Z</DateStart><DateChangeLast>2018-01-05T05:19:14Z</DateChangeLast><DateAdded>2016-10-26T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>University of Tsukuba Hospital ; Cardiovascular Division</Affiliation><Email>ktajiri@md.tsukuba.ac.jp</Email><Name>Kazuko Tajiri</Name><Phone>029-853-3143</Phone></Contact><Contact type="Scientific contact"><Affiliation>University of Tsukuba Hospital ; Cardiovascular Division</Affiliation><Name>Kazuko Tajiri</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Malignancy patients in the face of with anthracycline chemotherapy&lt;/li&gt;&lt;li&gt;Age &gt; 20 years old&lt;/li&gt;&lt;li&gt;EF&amp;gt; 50%&lt;/li&gt;&lt;li&gt;Life expectancy of&amp;gt; 1 year&lt;/li&gt;&lt;li&gt;Written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Cases with valuvular heart disease, gongenital heart disease, and cardiomyopathy&lt;/li&gt;&lt;li&gt;Pregnant or lactating women&lt;/li&gt;&lt;li&gt;Psychotic disorder&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The incidence of cardiotoxicity defined as a reduction in left ventricular ejection fraction (LVEF) &gt; 10 % points from baseline and &lt; 50%</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>All cause death, the following cardiac events (cardiac death, acute pulmonary edema, acute coronary syndromes, llife-threatening arrhythmias), the recovery from cadiotoxicity after the initiation of heart failure treatment defined as EF &gt; 50%</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study is to evaluate the incidence of anthracycline-induced cardiotoxicity and find predictive factors markers in cancer patients.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt; Patients will undergo echocardiac examination (before and  during anthracycline treatment, after 3, 6, 9, 12, 18, 24 months) after anthracycline treatment.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>University of Tsukuba Hospital</Name><Address1>Tsukuba</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Cancer supportive care</Disease><PatientSegments><PatientSegment><PatientSegment id="8984">Cancer/Treatment-related Cardiopulmonary Complications</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="12046">Other treatment induced toxicities</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000022984</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Cancer supportive care" id="19374"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Cancer supportive care" id="19380">Assessment of cardiac toxicity</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Cancer supportive care" id="19407"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Cancer supportive care" id="19399"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Cancer supportive care" id="19402">Assessment of time to all cause mortality</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Cancer supportive care" id="13338"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion></Inclusion><Inclusion disease="Cancer supportive care" id="13354"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13355">Subjects with history of anti-cancer chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cancer supportive care" id="22447"><Criterion>Other treatment induced toxicities</Criterion></Inclusion><Inclusion disease="Cancer supportive care" id="34403"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="13377">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Cancer supportive care" id="10881"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Cancer supportive care" id="10918"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Cancer supportive care" id="10935">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-10-26T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-01-05T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="316722"><TitleDisplay>Pilot Study on Weight Loss in Guinea Bissau</TitleDisplay><TitleOfficial>Pilot Study on Weight Loss in Guinea Bissau</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03316742</Identifier><Identifier type="Organisational Study">12377</Identifier></Identifiers><Indications><Indication id="238">Obesity</Indication></Indications><BiomarkerNames><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="17697" role="Therapeutic effect marker" type="Anthropomorphic">Body height</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>weight loss program</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1138790" type="Company"><TargetEntity id="5052167703" type="organizationId">Jean Mayer USDA Human Nutrition Research Center</TargetEntity></SourceEntity><SourceEntity id="20689" type="Company"><TargetEntity id="5029466201" type="organizationId">Tufts University</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"/><TargetEntity id="10029883" type="MEDDRA"/><TargetEntity id="D009765" type="MeSH"/><TargetEntity id="-1640888899" type="omicsDisease"/><TargetEntity id="985" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="5">Suspended</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20689">Tufts University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1138790">Jean Mayer USDA Human Nutrition Research Center</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Behavioral intervention</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>50</PatientCountEnrollment><DateStart>2019-01-31T00:00:00Z</DateStart><DateEnd type="estimated">2020-01-31T00:00:00Z</DateEnd><DateChangeLast>2019-01-25T17:35:18Z</DateChangeLast><DateAdded>2017-10-24T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Tufts University</Affiliation><Name>Susan B Roberts, PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Men and women who are overweight or obese (BMI &gt;/= 25 kg/m2)&lt;/li&gt;&lt;li&gt;Want to lose weight, want to enroll in the study and are willing to sign the informed consent form&lt;/li&gt;&lt;li&gt;Anticipate being able to meet the study requirements for food habits and study meetings, and anticipate remaining in Bissau for the study duration&lt;/li&gt;&lt;li&gt;Between the ages of 20 to 65 years&lt;/li&gt;&lt;li&gt;Non-pregnant women, and those who do not intend on becoming pregnant during the course of the study&lt;/li&gt;&lt;li&gt;A doctor or nurse has signed a note approving participant in the weight loss intervention after seeing a copy of the handout with title 'Instructions for Bissau Weight Loss Pilot Project', and a copy of his/her approval is given to the research staff&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Report food allergies or intolerance or health conditions that would prevent consumption of provided and recommended foods&lt;/li&gt;&lt;li&gt;Participation in another concurrent nutrition research study&lt;/li&gt;&lt;li&gt;If premenopausal (&amp;lt; 55 years of age), they are pregnant or intend to become pregnant during the course of the study, or are not using a birth control method to prevent pregnancy&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Change in weight: primary outcome is weight change between baseline and endline</Description><Timeframe>Week 1 to week 12</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Change in Blood Pressure: a secondary outcome is change in blood pressure between baseline and endline</Description><Timeframe>Baseline, week 12</Timeframe></Measure><Measure><Description>Change in Height: a secondary outcome is change in height between baseline and endline</Description><Timeframe>Week 1, week 12</Timeframe></Measure><Measure><Description>Change in self-reported demographics: a self administered demographics survey measures education, occupation, dietary food frequency and food security</Description><Timeframe>Baseline, week 12</Timeframe></Measure><Measure><Description>Change in self-reported measures of eating behavior: self-administered "Three Factor Eating Questionnaire" will be used to capture participants eating behavior between baseline and endline</Description><Timeframe>Baseline, week 12</Timeframe></Measure><Measure><Description>Change in self-reported measures of mood: self-administered 'Profile of Mood States Questionnaire' will be used to capture participants mood between baseline and endline</Description><Timeframe>Baseline, week 12</Timeframe></Measure><Measure><Description>Change in self-reported measures of physical activity: self-administered 'International Physical Activity Questionnaire' will be used to capture participants physical activity between baseline and endline</Description><Timeframe>Baseline, week 12</Timeframe></Measure><Measure><Description>Intervention Adherence: adherence to the designated intervention will be measured by self-reported dietary intake</Description><Timeframe>Week 1 to week 12</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to test two versions a weight loss program potentially suitable      for implementation in Africa. A successful method would have widespread application in      low-income countries, with the potential to improve world health.&lt;/para&gt;&lt;para&gt;Specific Aim 1 was to conduct a 3 to 4 month pilot study randomizing participants to two versions      of a weight loss program. The program will be implemented in a convenience sample of      overweight and obese adults living in Guinea-Bissau and measure changes in body weight loss      (primary outcome), adherence to program recommendations including recommended food patterns,      blood pressure, eating behavior, physical activity and mood (secondary outcomes). The data      would be used to refine the weight loss program and conduct power calculations for a future      trial.&lt;/para&gt;&lt;para&gt;Specific Aim 2 was to analyze associations between weight loss, participant demographics and      program metrics, to explore reasons for differences in weight loss between participants.      Factors to be tested include participant BMI, gender and age, as well as adherence to meal      portion recommendations, use of sugar-sweetened beverages and provided foods, and physical      activity.&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients randomized to intervention 1 would complete baseline and endline outcomes and participate in version 1 of a weight loss program. Each participant would attend twelve 1 h classes discussing weight loss adherence in addition to barriers experienced. Changes in weight would be recorded throughout the study.&lt;/para&gt;&lt;para&gt;Patients randomized to intervention 2 would complete baseline and endline outcomes and participate in version 2 of a weight loss program. Each participant would attend twelve 1 h classes discussing weight loss adherence in addition to barriers experienced. Changes in weight would be recorded throughout the study.&lt;br/&gt;&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><SuspensionReason>&lt;SuspensionReason&gt;&lt;para&gt;This trial was suspended as the study has not yet been approved by the local IRB in Guinea Bissau.&lt;/para&gt;&lt;/SuspensionReason&gt;</SuspensionReason></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Guinea-Bissau"><Sites><Site><Name>International Partnership for Health Development</Name><Address1>Bissau</Address1><Address3>1000</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Obesity</Disease><PatientSegments><PatientSegment><PatientSegment id="7733">Overweight (pre-obese) Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7734">Obese Class I Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7735">Obese Class II Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7736">Morbid Obesity(Class III) Subjects</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7752">Others</PatientSegment><SubSegments><SubSegment id="18680">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03316742</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Obesity" id="20791"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20400">Assessment of Body Weight</SubEndpoint><SubEndpoint disease="Obesity" id="20401">Assessment of weight loss</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Obesity" id="20427"><Endpoint>Assessment of Dietary Intake</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20444"><Endpoint>Assessment of Functional Disability/Physical Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20599"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20554">Assessment of blood pressure</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20623"><Endpoint>Assessment of Behavior Changes</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20779"><Endpoint>Assessment of compliance/adherence</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="20791"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20726">Assessment of height</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="29701"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="29739">Food frequency questionnaire(FFQ)</SubEndpoint><SubEndpoint disease="Obesity" id="29747">Assessment by International Physical Activity Questionnaire (IPAQ)</SubEndpoint><SubEndpoint disease="Obesity" id="29755">Assessment by Profile of Mood States (POMS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Obesity" id="44823"><Endpoint>Assessment of Neuropsychological Function</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Obesity" id="20791"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Obesity" id="20405">Assessment of BMI</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Obesity" id="19672"><Criterion>Obese Subjects</Criterion><SubCriteria><SubCriterion disease="Obesity" id="22429">Obese Class I Subjects</SubCriterion><SubCriterion disease="Obesity" id="22430">Obese Class II Subjects</SubCriterion><SubCriterion disease="Obesity" id="22433">Morbid Obesity(Class III) Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19678"><Criterion>Subjects with Protocol Specified BMI</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19680">Subjects with BMI&gt;25</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19787"><Criterion>Subjects with Protocol Specified Anthropometric Measurements</Criterion><SubCriteria><SubCriterion disease="Obesity" id="22428">Overweight Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="19790"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19815">Selection at the discretion of the physician</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="33949"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19753">Women with adequate contraception/Negative pregnancy test/Non-lactating women</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="34455"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19791">Subjects with compliance to informed consent process</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="34498"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19746">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Obesity" id="34819"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="19792">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Obesity" id="15364"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15368">Prior/Recent participating in clinical trial</SubCriterion><SubCriterion disease="Obesity" id="15382">Any medical/surgical condition interfering with participation in the study</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Obesity" id="24974"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Obesity" id="15397">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-10-13T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-10-24T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-09-24T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="337158"><TitleDisplay>An observational study on external beam radiation therapy and brachytherapy in patients with cervical cancer</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="427">Uterine cervix tumor</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>brachytherapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>cisplatin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>cobalt 60 external beam radiation therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1097293" type="Company"><TargetEntity id="5042953321" type="organizationId">Princess Margaret Cancer Centre</TargetEntity></SourceEntity><SourceEntity id="427" type="ciIndication"><TargetEntity id="C53" type="ICD10"/><TargetEntity id="10008342" type="MEDDRA"/><TargetEntity id="D002583" type="MeSH"/><TargetEntity id="-837567682" type="omicsDisease"/><TargetEntity id="590" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1097293">The Princess Margaret Cancer Centre</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Radiation therapy</Category></TrialCategories><PatientCountEnrollment>250</PatientCountEnrollment><PatientCountEvaluable>250</PatientCountEvaluable><DateChangeLast>2018-04-24T22:00:37Z</DateChangeLast><DateAdded>2018-04-24T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with cervical cancer&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients treated without brachytherapy or with palliative intent&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Overall survival and locoregional recurrence: from the date of first radiation therapy to the event date-or last follow-up when no event recurred-using the Kaplan-Meier (product-limit) method</Description></Measure><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In December 2017, results were published. Vaginal stenosis and shortening was the most commonly reported late side effect reported in 32% of patients [&lt;ulink linkType="Reference" linkID="2026984"&gt;2026984&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study was to evaluate the 	efficacy, toxicity, and cancer outcomes of external beam radiation therapy and brachytherapy in a large population of patients with cervical cancer from the National Centre for Radiotherapy in Accra, Ghana [&lt;ulink linkType="Reference" linkID="2026984"&gt;2026984&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In December 2017, results were published. The median overall treatment time was 73 days with median follow up period of 2.4 years. Three year overall survival and locoregional recurrence rates was 86 and 19%, respectively [&lt;ulink linkType="Reference" linkID="2026984"&gt;2026984&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients who received cobalt 60 external beam radiation therapy, followed by 	two low-dose-rate brachytherapy insertions and recommended concurrent cisplatin weekly from 2006 to 2011 were included and analyzed [&lt;ulink linkType="Reference" linkID="2026984"&gt;2026984&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Ghana"><Sites><Site><Name>National Centre for Radiotherapy</Name><Address2>Accra</Address2><CountrySubDivision>Accra</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-04-24T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="337964"><TitleDisplay>Early detection of acute kidney injury by L-FABP</TitleDisplay><TitleOfficial>Study of early detection of acute kidney injury using urinary L-type fatty acid binding protein (L-FABP)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000031973</Identifier></Identifiers><Indications><Indication id="3108">Renal injury</Indication></Indications><BiomarkerNames><BiomarkerName id="213" role="Disease marker" type="Biochemical">Creatinine</BiomarkerName><BiomarkerName id="1658" role="Disease marker" type="Genomic;Proteomic">Fatty acid-binding protein, liver</BiomarkerName><BiomarkerName id="11268" role="Disease marker" type="Physiological">Urinary flow</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="24739" type="Company"><TargetEntity id="5035529297" type="organizationId">Nara Medical University</TargetEntity></SourceEntity><SourceEntity id="3108" type="ciIndication"><TargetEntity id="S37.0" type="ICD10"/><TargetEntity id="10061481" type="MEDDRA"/><TargetEntity id="D058186" type="MeSH"/><TargetEntity id="1352" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="24739">Nara Medical University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biomarker identification</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>400</PatientCountEnrollment><DateStart>2018-04-15T00:00:00Z</DateStart><DateChangeLast>2018-08-21T06:55:00Z</DateChangeLast><DateAdded>2018-05-03T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Nara Medical University ; Department of Emergency and Critical Care</Affiliation><Email>asaih@naramed-u.ac.jp</Email><Name>Hideki Asai</Name><Phone>0744-22-3051</Phone></Contact><Contact type="Scientific contact"><Affiliation>Nara Medical University ; Department of Emergency and Critical Care</Affiliation><Email>asaih@naramed-u.ac.jp</Email><Name>Hideki Asai</Name><Phone>0744-22-3051</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;A-line and balloon insertion patient when entering ICU&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Comparison of variation of L-FABP and variation of creatinine in two groups with or without AKI onset</Description></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;By measuring L-FABP, investigators diagnose acute renal injury earlier than existing diagnostic criteria (serum creatinine or urine volume). Differences in the cause of acute renal injury such as trauma and intrinsic relation with L-FABP will be evaluated.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;A-line and balloon insertion patients will be included and observed.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Nara Medical University ; Department of Emergency and Critical Care</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Renal failure</Disease><PatientSegments><PatientSegment><PatientSegment id="11494">Subjects with Acute Renal Failure(ARF)</PatientSegment><SubSegments><SubSegment id="11496">Subjects in injury(I) category</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="11501">Hospitalized/ICU Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000031973</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Renal failure" id="22959"><Endpoint>Assessment of Renal Function</Endpoint><SubEndpoints><SubEndpoint disease="Renal failure" id="22961">Assessment of creatinine level</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Renal failure" id="22977"><Endpoint>Assessment of Organ Function</Endpoint><SubEndpoints><SubEndpoint disease="Renal failure" id="22980">Hepatic assessment</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Renal failure" id="23011"><Endpoint>Protocol Specified Other Endpoints</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Renal failure" id="20175"><Criterion>Subjects with Acute Renal Failure(ARF)</Criterion><SubCriteria><SubCriterion disease="Renal failure" id="20177">Subjects in injury(I) category</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Renal failure" id="20190"><Criterion>Hospitalized/ICU Subjects</Criterion></Inclusion></InclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-05-03T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="348119"><TitleDisplay>Study on Epigenetic Mechanism of Chronic Hepatitis B Syndrome Differentiation Based on DNA Methylation</TitleDisplay><TitleOfficial>Study on Epigenetic Mechanism of Chronic Hepatitis B Syndrome Differentiation Based on DNA Methylation</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR1800017365</Identifier></Identifiers><Indications><Indication id="152">Hepatitis B virus infection</Indication></Indications><BiomarkerNames><BiomarkerName id="2404" role="Disease marker" type="Genomic;Proteomic">DNA (cytosine-5)-methyltransferase 1</BiomarkerName><BiomarkerName id="4587" role="Disease marker" type="Genomic">Methyl-CpG-binding protein 2</BiomarkerName><BiomarkerName id="4627" role="Disease marker" type="Genomic">Cyclin-G1</BiomarkerName><BiomarkerName id="6581" role="Disease marker" type="Genomic">microRNA 122</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1073072" type="Company"><TargetEntity id="5037845335" type="organizationId">Chengdu University of Traditional Chinese Medicine</TargetEntity></SourceEntity><SourceEntity id="152" type="ciIndication"><TargetEntity id="10019731" type="MEDDRA"/><TargetEntity id="D019694" type="MeSH"/><TargetEntity id="-1284790527" type="omicsDisease"/><TargetEntity id="429" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1073072">Chengdu University of Traditional Chinese Medicine</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Gene therapy</Category><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2017-01-01T00:00:00Z</DateStart><DateEnd type="estimated">2019-12-31T00:00:00Z</DateEnd><DateChangeLast>2018-08-08T07:01:09Z</DateChangeLast><DateAdded>2018-08-03T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Chengdu University of TCM</Affiliation><Email>272624808@qq.com</Email><Name>Ma Li</Name><Phone>+86 13469613549</Phone></Contact><Contact type="Scientific contact"><Affiliation>Chengdu University of TCM</Affiliation><Email>zhengxiuli023@163.com</Email><Name>Zheng Xiuli</Name><Phone>+86 18081062358</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;It conforms the diagnostic criteria of Chronic Hepatitis B and TCM syndrome differentiation criteria at the same time&lt;/li&gt;&lt;li&gt;Aged between 18 and 60 years&lt;/li&gt;&lt;li&gt;Agree and sign the informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Concomitant with other types of hepatitis virus or/and HIV infection&lt;/li&gt;&lt;li&gt;Patients with cirrhosis or malignant tumors&lt;/li&gt;&lt;li&gt;Concomitant drug or toxic liver injury, autoimmune hepatitis, hereditary-metabolic liver disease&lt;/li&gt;&lt;li&gt;Unclear consciousness, unable to express subjective symptoms of discomfort and psychotic patients&lt;/li&gt;&lt;li&gt;Those with serious diseases such as heart, lung, kidney, endocrine and blood&lt;/li&gt;&lt;li&gt;The researchers found that other conditions were not suitable for participation in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>DNA methyltransferase</Description></Measure><Measure><Description>Methylated chip</Description></Measure><Measure><Description>Methylated DNA binds to the protein MeCP2</Description></Measure><Measure><Description>The target gene of mir-122 is cyclin G1</Description></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the study is to explore the differences of epigenetics between spleen-stomach damp heat syndrome and liver depression with spleen insufficiency in Chronic Hepatitis B.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients who are diagnosed with chronic hepatitis B will be observed.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Pixian hospital of TCM in Sichuan</Name><Address1>Sichuang</Address1><Address2>Sichuang</Address2><CountrySubDivision>Sichuang</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hepatitis B virus infection</Disease><PatientSegments><PatientSegment><PatientSegment id="19014">Subjects with Hepatitis B Infection</PatientSegment><SubSegments><SubSegment id="10099">Subjects with Chronic Hepatitis B Infection</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR1800017365</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Hepatitis B virus infection" id="18324"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Hepatitis B virus infection" id="18295"><Endpoint>Assessment of Liver Functions</Endpoint></OtherEndpoint><OtherEndpoint disease="Hepatitis B virus infection" id="18315"><Endpoint>Assessment of Non-hepatic Morbidities</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Hepatitis B virus infection" id="16775"><Criterion>Subjects with Chronic Hepatitis B Infection</Criterion></Inclusion><Inclusion disease="Hepatitis B virus infection" id="16825"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Hepatitis B virus infection" id="34328"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Hepatitis B virus infection" id="33196">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Hepatitis B virus infection" id="14254"><Criterion>Subjects with Other Hepatitis Virus Infections</Criterion></Exclusion><Exclusion disease="Hepatitis B virus infection" id="14260"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Hepatitis B virus infection" id="14262">Subjects co-morbid with Liver cirrhosis</SubCriterion><SubCriterion disease="Hepatitis B virus infection" id="14263">Subjects co-morbid with auto-immune hepatitis/liver disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hepatitis B virus infection" id="14267"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Hepatitis B virus infection" id="14268"><Criterion>Subjects co-morbid with CNS disorders</Criterion></Exclusion><Exclusion disease="Hepatitis B virus infection" id="14269"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Hepatitis B virus infection" id="14270"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Hepatitis B virus infection" id="14272"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Hepatitis B virus infection" id="14273"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion></Exclusion><Exclusion disease="Hepatitis B virus infection" id="14274"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Hepatitis B virus infection" id="14275"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Hepatitis B virus infection" id="14276">Subjects immunocompromized with HIV infection</SubCriterion><SubCriterion disease="Hepatitis B virus infection" id="14277">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hepatitis B virus infection" id="14280"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Hepatitis B virus infection" id="14302"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Hepatitis B virus infection" id="27847"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-08-03T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="351121"><TitleDisplay>Endovascular exclusion technique for the treatment of complex basis cranii vessel wall defects: a prospective, multicenter clinical trial</TitleDisplay><TitleOfficial>Endovascular exclusion technique for the treatment of complex basis cranii vessel wall defects: a prospective, multicenter clinical trial</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR1800017756</Identifier></Identifiers><Indications><Indication id="742">Vascular disease</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Willis coverted stent</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1073081" type="Company"><TargetEntity id="5037845405" type="organizationId">Shanghai Tongji Hospital</TargetEntity></SourceEntity><SourceEntity id="1130164" type="Company"><TargetEntity id="5052124307" type="organizationId">Tongji University School of Medicine</TargetEntity></SourceEntity><SourceEntity id="742" type="ciIndication"><TargetEntity id="10059245" type="MEDDRA"/><TargetEntity id="D014652" type="MeSH"/><TargetEntity id="-90096021" type="omicsDisease"/><TargetEntity id="3754" type="siCondition"/><TargetEntity id="1157" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>3</NumberOfSites><CompaniesSponsor><Company id="1073081">Tongji Hospital</Company><Company id="1130164">Tongji University School of Medicine</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>50</PatientCountEnrollment><DateStart>2018-08-30T00:00:00Z</DateStart><DateEnd type="estimated">2021-10-30T00:00:00Z</DateEnd><DateChangeLast>2018-08-29T12:06:53Z</DateChangeLast><DateAdded>2018-08-27T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Shanghai Tongji Hospital, Tongji University School of Medicine</Affiliation><Email>fang1972@vip.sina.com</Email><Name>Chun Fang</Name><Phone>+86 13402099739</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Cerebral angiography examinations confirmed complicated cerebral aneurysms (wide-necked/large or giant/ pseudo-aneurysm) at internal or vertebral arteries&lt;/li&gt;&lt;li&gt;Wide-necked aneurysm is considered as the neck width &gt;/= 4 mm or fundus-to-neck ratio&amp;lt; 2; large or giant aneurysms are defined as the maximum aneurysm diameter between 10 to 25 mm or &gt;/= 25 mm; Pseudo-aneurysm is considered definitely caused by trauma, iatrogenic injury or radiotherapy et al&lt;/li&gt;&lt;li&gt;Diameter of the parent artery is between 3.5 to 4.5 mm&lt;/li&gt;&lt;li&gt;Researchers believe patients is suitable to receive WILLIS covered stent treatment&lt;/li&gt;&lt;li&gt;Patients volunteered to conduct the study and sign the informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Important side branches originate from the target aneurysm, including anterior choroidal artery, embryonic type of the posterior communicating artery and posterior inferior cerebellar artery&lt;/li&gt;&lt;li&gt;No appropriate vessel routes or extremely tortuous parent arteries&lt;/li&gt;&lt;li&gt;Sever coagulation disorders, dysfunction of the heart, liver or kidney or systemic infection&lt;/li&gt;&lt;li&gt;Life expectancy&amp;lt; 1 year&lt;/li&gt;&lt;li&gt;There are contraindications for heparin, aspirin, clopidogrel, anesthesia, contrast media or X-ray&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Aneurysm total occlusion rate</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Patency of parent artery</Description></Measure><Measure><Description>Procedure related safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Objectives of study: To assess the eficiency of clinical application of the Willis coverted stent for the treatment of complex basis cranii vessel wall defects.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients treated with Willis coverted stent insertion will be observed.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Shanghai Tongji Hospital, Tongji University School of Medicine</Name><Address1>Putuo</Address1><Address2>Shanghai</Address2><CountrySubDivision>Shanghai</CountrySubDivision><Contacts/></Site><Site><Name>Shanghai No.6th People's Hospital</Name><Address1>Xuhui</Address1><Address2>Shanghai</Address2><CountrySubDivision>Shanghai</CountrySubDivision><Contacts/></Site><Site><Name>Shanghai East campus of the No.6th People`s Hospital</Name><Address1>Pudong New Area</Address1><Address2>Shanghai</Address2><CountrySubDivision>Shanghai</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other cardiovascular disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18214">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="14552">Subjects with aneurysm</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR1800017756</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other cardiovascular disease" id="43649"><Endpoint>Clinical Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other cardiovascular disease" id="42861"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other cardiovascular disease" id="43649"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other cardiovascular disease" id="32809"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other cardiovascular disease" id="34312"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other cardiovascular disease" id="32944">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other cardiovascular disease" id="35068"><Criterion>Subjects with specific disease</Criterion></Inclusion><Inclusion disease="Other cardiovascular disease" id="35436"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Other cardiovascular disease" id="35437">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other cardiovascular disease" id="23962"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="24099"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Other cardiovascular disease" id="29934">Subjects unsuitable for study participation as per investigator's assessment</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other cardiovascular disease" id="26092"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="26268"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="29932"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="29933"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-08-27T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="374203"><TitleDisplay>Study on the Clinical Efficacy of Optimized Qinggan Jieyu Decoction in Treating Liver Depression and Heat Syndrome</TitleDisplay><TitleOfficial>Study on the Clinical Efficacy of Optimized Qinggan Jieyu Decoction in Treating Liver Depression and Heat Syndrome</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR1900021839</Identifier></Identifiers><Indications><Indication id="210">Migraine</Indication><Indication id="3288">Non alcoholic fatty liver disease</Indication><Indication id="480">Premenstrual syndrome</Indication><Indication id="750">Insomnia</Indication></Indications><BiomarkerNames><BiomarkerName id="113" role="Therapeutic effect marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="133" role="Therapeutic effect marker" type="Biochemical">Total cholesterol</BiomarkerName><BiomarkerName id="152" role="Therapeutic effect marker" type="Biochemical">Low-density lipoprotein cholesterol</BiomarkerName><BiomarkerName id="176" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-6</BiomarkerName><BiomarkerName id="217" role="Therapeutic effect marker" type="Biochemical">Triglycerides</BiomarkerName><BiomarkerName id="1211" role="Therapeutic effect marker" type="Genomic;Proteomic">Alanine transaminase</BiomarkerName><BiomarkerName id="2527" role="Therapeutic effect marker" type="Genomic;Proteomic">Aspartate aminotransferase</BiomarkerName><BiomarkerName id="2613" role="Therapeutic effect marker" type="Biochemical">Norepinephrine</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Qinggan Jieyu decoction</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1010249" type="Company"><TargetEntity id="5035533220" type="organizationId">Dongzhimen Hospital</TargetEntity></SourceEntity><SourceEntity id="210" type="ciIndication"><TargetEntity id="G43" type="ICD10"/><TargetEntity id="10027599" type="MEDDRA"/><TargetEntity id="D008881" type="MeSH"/><TargetEntity id="-672899670" type="omicsDisease"/><TargetEntity id="27" type="siCondition"/></SourceEntity><SourceEntity id="3288" type="ciIndication"><TargetEntity id="K76.0" type="ICD10"/><TargetEntity id="-468189475" type="omicsDisease"/><TargetEntity id="2263" type="siCondition"/></SourceEntity><SourceEntity id="480" type="ciIndication"><TargetEntity id="10036618" type="MEDDRA"/><TargetEntity id="D011293" type="MeSH"/><TargetEntity id="-1413662353" type="omicsDisease"/><TargetEntity id="59" type="siCondition"/></SourceEntity><SourceEntity id="750" type="ciIndication"><TargetEntity id="G47.0" type="ICD10"/><TargetEntity id="10022437" type="MEDDRA"/><TargetEntity id="76" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1010249">Dongzhimen Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category><Category>Herbal preparation</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Active Control</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>120</PatientCountEnrollment><DateStart>2019-03-12T00:00:00Z</DateStart><DateEnd type="estimated">2020-04-12T00:00:00Z</DateEnd><DateChangeLast>2019-03-25T12:38:13Z</DateChangeLast><DateAdded>2019-03-22T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Dongzhimen Hospital, Beijing University of Chinese Medicine</Affiliation><Email>zhoubokingkong@163.com</Email><Name>Bo Zhou</Name><Phone>+86 18911244036</Phone></Contact><Contact type="Scientific contact"><Affiliation>Dongzhimen Hospital, Beijing University of Chinese Medicine</Affiliation><Email>gaoying973@126.com</Email><Name>Ying Gao</Name><Phone>+86 010 84013148</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Aged 18 to 65 years, regardless of gender&lt;/li&gt;&lt;li&gt;Patients who are in accordance with TCM syndrome differentiation for liver stagnation and heat syndrome&lt;/li&gt;&lt;li&gt;Sign the informed consent form&lt;/li&gt;&lt;li&gt;Comply with Western medicine for diagnosis of migraine or non-organic insomnia or premenstrual syndrome or nonalcoholic fatty liver disease&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Those who have obvious syndromes or combined syndromes&lt;/li&gt;&lt;li&gt;Those who are using other interventions are being treated&lt;/li&gt;&lt;li&gt;Severe primary diseases such as heart, liver, brain, kidney and hematopoietic system, or mental patients&lt;/li&gt;&lt;li&gt;Pregnancy or preparation for pregnancy, lactating women&lt;/li&gt;&lt;li&gt;Those who are known to be allergic to this type of drug and have serious allergies&lt;/li&gt;&lt;li&gt;Patients who participated in other clinical drug trials in the past 3 months&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Liver stagnation heat syndrome syndrome evaluation scale</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Number of headache attacks and half the rate of seizures</Description></Measure><Measure><Description>Day of headache</Description></Measure><Measure><Description>Migraine based on patient-reported outcome rating scale</Description></Measure><Measure><Description>BMI</Description></Measure><Measure><Description>Aspartate aminotransferase, alanine aminotransferase, triglyceride, cholesterol, low density lipoprotein</Description></Measure><Measure><Description>Hepatic B ultrasound</Description></Measure><Measure><Description>SF-36 Quality of Life Scale Chinese version</Description></Measure><Measure><Description>Norepinephrine, IL-6</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;Study objectives:&lt;br/&gt;Evaluation of the optimization of Qinggan Jieyu decoction in the treatment of liver stagnation and heat syndrome (migraine, non-organic insomnia, premenstrual syndrome, non-alcoholic fatty liver disease) syndrome changes and clinical efficacy. &lt;br/&gt;To explore the mechanism of the optimized Qinggan Jieyu decoction in the treatment of liver stagnation and heat syndrome.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients (migraine, non-organic insomnia, premenstrual syndrome, non-alcoholic fatty liver disease; n = 30 in each group) will receive optimized Qinggan Jieyu decoction.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Dongzhimen Hospital, Beijing University of Chinese Medicine</Name><Address1>Dongcheng District</Address1><Address2>Beijing</Address2><CountrySubDivision>Beijing</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other gastrointestinal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18219">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="18805">Subjects with Non alcoholic fatty liver disease</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Other gynecological disorder</Disease><PatientSegments><PatientSegment><PatientSegment id="17446">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="17991">Subjects co-morbid with Premenstrual Syndrome</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR1900021839</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Insomnia" id="23612"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Insomnia" id="23644"><Endpoint>Clinical Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other gastrointestinal disease" id="42974"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other gastrointestinal disease" id="43526"><Endpoint>Clinical Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Migraine" id="47686"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Insomnia" id="23572"><Endpoint>Assessment of Sleep</Endpoint><SubEndpoints><SubEndpoint disease="Insomnia" id="23590">Assessment by Pittsburgh Sleep Quality Index (PSQI)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insomnia" id="23612"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Insomnia" id="33738">Assessment by Short Form Health Survey (SF-36)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insomnia" id="23644"><Endpoint>Clinical Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Insomnia" id="23648">Assessment of liver function</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insomnia" id="23646"><Endpoint>Anthropometric Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insomnia" id="23652"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Insomnia" id="23658">Assessment of Inflammatory/Immunological Markers</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insomnia" id="23689"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other gastrointestinal disease" id="42974"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other gastrointestinal disease" id="43397"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other gastrointestinal disease" id="43414"><Endpoint>Assessment of Liver Functions</Endpoint><SubEndpoints><SubEndpoint disease="Other gastrointestinal disease" id="43415">Serum glutamic oxaloacetic transaminase (SGOT)/aspartate aminotransferase (AST)</SubEndpoint><SubEndpoint disease="Other gastrointestinal disease" id="43416">Serum glutamic-pyruvic transaminase (SGPT)/alanine aminotransferase (ALT)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other gastrointestinal disease" id="43526"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other gastrointestinal disease" id="43528"><Endpoint>Imaging/Radiological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Migraine" id="44150"><Endpoint>Assessment of Clinical Symptoms</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Migraine" id="44154"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Migraine" id="47694">Other laboratory assessments</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insomnia" id="44899"><Endpoint>Assessment of Clinical Symptoms</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insomnia" id="44961"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Insomnia" id="23654">Assessment of imaging modalities</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other gastrointestinal disease" id="46262"><Endpoint>Protocol Specified Other Endpoints</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other gastrointestinal disease" id="46282"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Other gastrointestinal disease" id="46283">Assessment of BMI</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other gastrointestinal disease" id="46286"><Endpoint>Assessment of lipid profiles</Endpoint><SubEndpoints><SubEndpoint disease="Other gastrointestinal disease" id="46287">Assessment of low density lipoprotein cholesterol (LDL-C)</SubEndpoint><SubEndpoint disease="Other gastrointestinal disease" id="46289">Assessment of Total Cholesterol</SubEndpoint><SubEndpoint disease="Other gastrointestinal disease" id="46295">Assessment of Triglycerides</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Other gastrointestinal disease" id="46310"><Endpoint>Assessment of Sleep</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Migraine" id="47686"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other gastrointestinal disease" id="48790"><Endpoint>Assessment of Hormone Levels</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Insomnia" id="20407"><Criterion>Subjects with Diagnosis of Insomnia</Criterion></Inclusion><Inclusion disease="Insomnia" id="20496"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other gynecological disorder" id="32696"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Other gynecological disorder" id="33531">Subjects co-morbid with Premenstrual Syndrome</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other gastrointestinal disease" id="32953"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other gynecological disorder" id="33094"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other gastrointestinal disease" id="34319"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other gastrointestinal disease" id="32955">Subjects able/willing to provide written informed consent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other gastrointestinal disease" id="35070"><Criterion>Subjects with specific disease</Criterion></Inclusion><Inclusion disease="Other gastrointestinal disease" id="35312"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Inclusion><Inclusion disease="Migraine" id="35669"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Migraine" id="35672"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Inclusion><Inclusion disease="Migraine" id="35673"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Migraine" id="35674">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other gynecological disorder" id="35833"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other gynecological disorder" id="35834">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Insomnia" id="18219"><Criterion>Subjects co-morbid with Psychiatric Disease/Disorder</Criterion></Exclusion><Exclusion disease="Insomnia" id="18227"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Insomnia" id="18229"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Insomnia" id="18231"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Insomnia" id="18237"><Criterion>Subjects co-morbid with immunological disease/disorder</Criterion></Exclusion><Exclusion disease="Insomnia" id="18286"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other gastrointestinal disease" id="24021"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Other gastrointestinal disease" id="25191">Immune disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other gynecological disorder" id="24055"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Migraine" id="24279"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other gastrointestinal disease" id="24301"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other gynecological disorder" id="24303"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other gastrointestinal disease" id="24468"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Other gastrointestinal disease" id="24596"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Migraine" id="24750"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Migraine" id="24751">Subjects with liver diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Migraine" id="24754"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Migraine" id="24755"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Migraine" id="24954"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Migraine" id="24748">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other gastrointestinal disease" id="24958"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other gastrointestinal disease" id="24372">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other gastrointestinal disease" id="25161"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Other gastrointestinal disease" id="25163">Subjects with abnormal hematological tests</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other gastrointestinal disease" id="25170"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion></Exclusion><Exclusion disease="Other gastrointestinal disease" id="25174"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Insomnia" id="25558"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Insomnia" id="24746">Subjects unable/unwilling to give informed consent</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other gastrointestinal disease" id="25772"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Insomnia" id="26052"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Insomnia" id="18232">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insomnia" id="26518"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Insomnia" id="26860"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion><Exclusion disease="Migraine" id="27227"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion><Exclusion disease="Insomnia" id="27870"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion><Exclusion disease="Other gynecological disorder" id="27914"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion></Exclusion><Exclusion disease="Insomnia" id="28309"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion><Exclusion disease="Other gynecological disorder" id="28328"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion><Exclusion disease="Other gynecological disorder" id="29146"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion><Exclusion disease="Other gastrointestinal disease" id="29150"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion><Exclusion disease="Migraine" id="29192"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion><Exclusion disease="Other gynecological disorder" id="29916"><Criterion>Subjects with Abnormal Organ Function</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-03-22T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial></trialRecordsOutput>